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220Background: Little is known about the prevalence of self-reported photosensitivity (PS) and its effects on
quality of life in a US cutaneous lupus population.Objective: We sought to determine the prevalence of self-reported PS among a cutaneous lupus
population and to examine its impact on quality of life.Methods: A total of 169 patients with lupus were interviewed about PS symptoms and completed the
modified Skindex-2913, a quality-of-life survey. A complete skin examination was conducted and the
Cutaneous Lupus Erythematosus Disease Area and Severity Index was completed.Results: In all, 68% of patients reported some symptoms of PS. The PS group (those who reported a history
of and current PS) scored worse on PS-related items of the modified Skindex-2913 and had higher
cutaneous disease activity as determined by the Cutaneous Lupus Erythematosus Disease Area and Severity
Index. Patients with PS had worse symptoms and emotions and experienced significant functional
impairments compared with patients who had cutaneous lupus without PS.Limitations: This study was done at a single referral center.Conclusions: Self-reported PS is very common among patients with cutaneous lupus and is associated
with significant impairments related to symptoms, emotions, and daily functioning. ( J Am Acad Dermatol
2012;66:220-8.)
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ltraviolet radiation (UVR) may play a role in
the development and exacerbation of lupus
erythematosus (LE). Because cutaneous
manifestations of LE often arise in sun-exposed
areas and exposure to environmental UVR can elicit
skin lesions, patients with LE are often labeled
‘‘photosensitive.’’1-4 The term ‘‘photosensitivity’’
(PS), however, is ill defined and is often used to
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defines PS, one of the criteria for diagnosis of
systemic LE (SLE), as ‘‘an unusual reaction to sunlight
by a patient’s history or by physician observation.’’6
This definition is very broad and encompasses
both self-reported symptoms and clinically apparent
reactions to UVR. Provocative phototesting has
been used to test PS in a more objective manner.
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Foering et al 221morphologically, and histologically consistent with
lupus and occurs in the typical delayed time course
attempts to define PS among a LE population.3,7 This
measure of PS, however, is influenced by a variety of
factors including but not limited to type and amount
of UVR, site and size of skin exposure, and patient
skin type. Moreover, results of provocative photo-CAPSULE SUMMARY
d Patients with lupus erythematosus are
commonly described as photosensitive.
d Self-reported photosensitivity is
common among a cutaneous lupus
erythematosus population and impacts
quality of life, most profoundly in terms
of functioning.
d Physicians need to be aware of the
impact of photosensitivity on quality of
life when counseling patients about
photoprotection.testing are often incongruent
with a patient’s history of
PS.5,8,9
Not surprisingly, the prev-
alence of PS in patients
with LE varies widely de-
pending on the definition
used, LE subtype, race, and
geographic location.10-12 Ac-
cording to the ACR definition
of PS, 57% to 73% of patients
with SLE, 50% to 90% with
subacute cutaneous LE
(SCLE), approximately 50%
with discoid LE (DLE), and
nearly all with tumid LE
(LET) are PS.8,13-21 Similarly,
broad prevalence figures for PS assessed by pro-
vocative phototesting have been reported, which
range from 10% to 74% for SLE, 50% to 100% for
SCLE, 16% to 64% for DLE, and 76% to 81% for
LET.2,3,22-27
Irrespective of patient history or phototesting
assessment, patients with LE are advised to avoid
sunlight to prevent lupus flares. Wearing long
clothes and a hat year-round, avoiding sun between
10 AM and 2 PM, and reapplying sunscreen several
times throughout the day are not trivial tasks.
Compliance with sun avoidance limits patients’
ability to take part in day-to-day activities, hobbies,
and social gatherings, which can significantly impact
quality of life. In a study of patients with SLE in the
United States, more than one third of patients
reported that PS (by patient assessment using a
visual analog scale) had a significant impact on their
quality of life.14
In this cross-sectional analysis of an ongoing
database study, we sought to determine the preva-
lence of self-reported PS in a US population of
patients with primarily cutaneous LE (CLE) and to
examine the impact of PS on quality of life.
Secondary objectives were to begin to validate clin-
ical interview questions used to ascertain self-
reported PS and the modified Skindex-2913 PS
items and PS subscale, and to examine the relation-
ship between PS and cutaneous lupus disease activ-
ity using the CLE Disease Area and Severity Index
(CLASI).METHODS
Patient selection
Patients with LE presenting to the outpatient med-
ical dermatology clinic at the University of
Pennsylvania were consecutively enrolled in our
ongoing database study on the prevalence and se-
verity of LE. All patients older than 18 years withclinical, histologic, and/or se-
rologic evidence of cutane-
ous lupus and/or SLE with
skin manifestations were in-
vited to participate. Patients
were categorized according
to the modified classification
of Gilliam and Sontheimer28
into the various subtypes of
CLE: acute CLE (ACLE), SCLE
(annular or papulosqua-
mous), and chronic CLE
(CCLE) (classic DLE [general-
ized or localized], hypertro-
phic DLE, LET, chilblains, or
lupus panniculitis). Patients
with SLE who met theAmerican Rheumatism Association/ACR criteria6
were included if they also had a form of CLE or had
lupus-nonspecific skin manifestations (including but
not limited to livedo reticularis, Raynaud phenome-
non, ulceration). The protocol for the study was
approved by the institutional review board of the
University of Pennsylvania School of Medicine and
was in accordance with the Declaration of Helsinki in
its current form. All patients provided institutional
review boardeapproved informed consent and
Health Insurance Portability and Accountability Act
forms.
Study procedures
Study visits were completed at the time of the
patient’s regularly scheduled clinic visit. Every effort
was made to conduct a study visit at the time of
enrollment. On occasions when this was not feasible,
the first study visit was completed at the next
scheduled clinic visit. Thereafter, study visits were
conducted as often as the patient was willing or if in
the interim since the last study visit any of the
following criteria were met: (1) the patient had a
change in symptoms (disease significantly worsened
or improved); (2) the patient had a change in
medication (started or stopped a medication); or
(3) it had been greater than 1 year since the last study
visit.
Information was obtained by patient history,
physical examination, medical record review, and
patient questionnaires. Immediately before the clinic
Abbreviations used:
ACLE: acute cutaneous lupus erythematosus
ACR: American College of Rheumatology
ANOVA: analysis of variance
CCLE: chronic cutaneous lupus erythematosus
CLASI: Cutaneous Lupus Erythematosus Disease
Area and Severity Index
CLE: cutaneous lupus erythematosus
DLE: discoid lupus erythematosus
LE: lupus erythematosus
LET: tumid lupus erythematosus
PS: photosensitivity
SCLE: subacute cutaneous lupus erythematosus
SLE: systemic lupus erythematosus
UVR: ultraviolet radiation
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naires, including the modified Skindex-2913 to
complete in the waiting area. During the study visit,
sociodemographic information and medical history
was collected. The patient was interviewed about
smoking and sun exposure, SLE symptoms, comor-
bid autoimmune conditions, medication effective-
ness, and side effects. A complete skin examination
was performed and the CLASI outcome measure was
completed. Whenever available, recent laboratory
values, including lupus serologies, biopsy results, or
both, were reviewed and documented.PS items and visit selection
At each visit, patients were asked the following
two questions to ascertain self-reported PS:
1. Do you have a history of PS?
2. Since the last visit, have you been experiencing
sensitivity to sunlight?
Any adverse reaction to sunlight reported by the
patient was recorded as a ‘‘yes.’’ Patient reports of
sensitivity to sunlight included but were not limited
to: sun brings out my lupus lesions, sun causes me to
get a rash, I feel sick in the sun, andmy skin tingles in
the sun. Based on answers to these two PS questions,
patients were classified into one of 3 PS groups: PS
group, PS-suggestive group, and not-PS group. To
avoid overrepresentation by one patient, only one
visit per patient was selected for analysis (Table I). In
addition to the above PS questions, at each visit
patients were asked about the frequency with which
they used sun protection and development of lupus
lesions in sun-exposed areas:
d Do you protect your skin from the sun with sun-
protective clothing and/or sunscreen? [Answer
options: daily, usually, sometimes, rarely, never.]
d Do you have lesions in sun-exposed areas? [An-
swer options: yes, no.]Modified Skindex-2913
The Skindex-29 is a validated measure of skin-
specific quality of life.29-32 The impact of skin on
functioning, symptoms, and emotions is assessed by
self-report. The level of agreement with items
corresponding to the 3 subscales is assessed on a
5-point Likert scale (never, rarely, sometimes, often,
all the time). Individual items are scored from 0 to
100 in 25-point increments with 100 representing
maximal disability. The subscales are determined by
taking the mean of the items that represent that
subscale. Three lupus-specific items were added to
the Skindex-29 to create the modified Skindex-
2913.33 Two items, ‘‘I worry about going outside
because the sun might flare my disease’’ and ‘‘My
skin disease prevents me from doing outdoor activ-
ities’’ relate to PS. The average of these two items was
used to generate a PS subscale.
CLE Disease Area and Severity Index
The CLASI is a validated tool to assess disease
severity in CLE.34-37 It quantifies disease activity
(erythema, scale) and damage (dyspigmentation,
scar) over 13 distinct areas of the body. Activity
and damage scores range from 0 to 70 and 0 to 56,
respectively, with higher scores representing more
severe disease. Disease activity is classified into mild
(0-9) and moderate to severe ($ 10) by CLASI
activity score.
Data collection
Data were collected in accordance with good
clinical practice guidelines to ensure accuracy and
integrity. Completeness of data and use of explicit
definitions for variables were assessed and a con-
stant effort at quality control was maintained. Data
were then organized and entered into a collaborative
World Wide Webebased database. Data security and
confidentiality were managed carefully to ensure
regulatory adherence.
Statistical analysis
Descriptive statistics including the frequency,
means (M), and SD of outcome variables were
generated. Contingency tables with Pearson x2 anal-
yses were used to compare frequencies between
groups. Student t tests were used to determine mean
differences in CLASI activity scores between groups.
Mean differences in the PS items and PS scale of the
modified Skindex-2913 were subjected to analysis
of variance (ANOVA). Mean differences in the 3
modified Skindex-2913 scales (symptoms, emo-
tions, function) were compared by two-factor (PS,
CLASI activity) ANOVA. The relationship among PS,
CLASI activity, and quality-of-life measures on the










SLE nonspecific 12 7
[1 CLE subtype* 7 4
CCLE other 4 2
Race
Caucasian 111 66




ACLE, Acute cutaneous lupus erythematosus; CCLE, chronic
cutaneous lupus erythematosus; CLE, cutaneous lupus
erythematosus; DLE, discoid lupus erythematosus; LET, tumid lupus
erythematosus; SCLE, subacute cutaneous lupus erythematosus;
SLE nonspecific, nonspecific skin manifestations (eg, livedo
reticularis) that met criteria for systemic lupus erythematosus.
*Four with SCLE1DLE; one with SCLE1ACLE; one with ACLE1LET;
one with DLE1panniculitis.
Table I. Photosensitivity classification and visit selection
History of PS
Current PS
symptoms Visit selected for analysis PS grouping
At $ 1 visits, patient answered: Yes Yes First visit in which patient
answered ‘‘yes’’/’’yes’’
PS group
If patient never answered ‘‘yes’’/’’yes,’’
but answered ‘‘yes’’ to either
question at $ 1 visits:





If patient never answered ‘‘yes’’
to either question at any visit:
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group into high/low PS and mild/moderate-severe
activity. The high PS group comprised patients
scoring greater than the mean PS scale score and
the low PS group scored less than the mean. Mild
activity group was classified as less than or equal to 9
CLASI activity and the moderate-severe activity
group comprised patients scoring more than 9 on
the CLASI.38 Mean Skindex scores within the 4 PS
group strata were subjected to ANOVA. Two-tailed
tests of significance level with type I (a) error rate of
0.05 were used.
RESULTS
A total of 169 patients were enrolled in the study.
In all, 80% were women and 20% were men. Nearly
half of the sample was given the diagnosis of DLE
(46%), 25% had SCLE, 9% had LET, 7% had ACLE, 7%
had SLE and nonspecific skin manifestations, 4% had
more than CLE subtype, and 2% had other forms of
CCLE (including panniculitis or chilblains). The
greater than one CLE subtype category comprised 4
patients with SCLE and DLE and one of each with
SCLE and ACLE, SCLE and LET, and DLE and
panniculitis. Two thirds of patients were Caucasian,
28% were African American, 5% were Asian, and one
patient was Hispanic (Table II).
Prevalence of PS
Of the 169 patients, 91 had both a history of and
ongoing PS, 11 had a history of PS, 13 had new-onset
PS, 40 did not experience PS, and in 14 patients we
were unable to determine PS status because of
incomplete information. Overall, 68% of the sample
reported symptoms of PS whereas only 24% of
patients denied PS. Of patients, approximately 82%
with ACLE, 76% with SCLE, 71% with more than one
CLE subtype, 63% with LET, 58% with SLE and
nonspecific skin manifestations, 46% with DLE, and
none with CCLE (panniculitis or chilblains) reported
both a history of and current PS (and were classified
into PS group) (Fig 1).PS group characteristics
Of the 91 patients comprising the PS group, 35%
had DLE, 31% had SCLE, 11% had LET, 10% had
ACLE, 8% had SLE with nonspecific skin manifesta-
tions, and 5% had more than one CLE subtype. There
was a significant association between two lupus
subtypes (DLE, SCLE) and PS grouping (Pearson
x2 = 17.92, P = .006). Patients with SCLE were more
likely to be categorized into the PS group whereas
patients with DLE were more likely to be classified
into the not-PS group. There was no significant
relationship between any of the other LE diagnoses
(ACLE, LET, SLE with nonspecific skin manifesta-
tions, [1 CLE subtype, and other CCLE) and PS
grouping.
Fig 1. Prevalence of photosensitivity (PS ) within each
lupus erythematosus (LE) type. More than 75% of patients
with acute cutaneous LE (ACLE ), subacute cutaneous LE
(SCLE ), and more than one cutaneous LE (CLE ) subtype
(comprising mostly SCLE 1 another type of CLE) were PS
whereas patients with discoid LE (DLE ) were least PS with
prevalence of 45%. CCLE, Chronic CLE; LET, tumid LE; SLE,
systemic LE.
Fig 2. Mean scores for photosensitivity (PS ) items of
modified Skindex-2913. Mean scores (mean 1 SEM) for
PS items and PS subscale by PS grouping. Significant
differences between PS and *not-PS or #PS-suggestive
groups; P\.05 with Bonferroni correction after analysis of
variance.
J AM ACAD DERMATOL
FEBRUARY 2012
224 Foering et alSun exposureerelated characteristics in PS
group versus not-PS group
The PS group developed lesions in sun-exposed
areas significantly more frequently than the not-PS
group (71% vs 31%, x2 = 5.88, P = .015). The PS group
engaged in sun-protective behaviors significantly
more frequently than the not-PS group (x2 = 16.63,
P = .002).
PS items of the modified Skindex-2913
ANOVA showed that the effect of PS was signif-
icant for item 31 (F = 19.51, P = .000), item 33 (F =
16.18, P = .000), and the PS scale (F = 21.58, P = .000).
The PS group scored significantly worse on item 31,
‘‘I worry about going outside because the sun might
flare my disease’’ (M = 74.2, SD = 28.9 vs M = 40, SD =
29.3 in not-PS group), and on the PS scale (average of
items 31 and 33) (M = 55.7, SD = 27.1 vs M = 35.9,
SD = 26.4 in not-PS group) compared with the not-PS
group. For item 33, ‘‘My skin disease prevents me
from doing outdoor activities,’’ the PS group scored
significantly worse (M = 65.9, SD = 33.2) than the PS-
suggestive (M = 46.8, SD = 34.0) and even more so
compared with the not-PS group (M = 31.8, SD =
28.9) (Fig 2).
CLASI activity and PS
ANOVA showed that the effect of PS was signif-
icant for CLASI activity score (F = 8.30, P = .005).
Patients in the PS group had significantly increased
lupus-specific cutaneous disease activity as mea-
sured by the CLASI activity score compared with
patients in the not-PS group (M = 9.2, SD = 9.4 vs M =4.6, SD = 5.6). A linear regression analysis with CLASI
activity as the response variable and PS (yes/no) as
the independent variable was statistically significant
(F = 8.30, P = .005). CLASI activity was moderately
correlated (r = 0.36) with the presence/absence of PS
(Table III).Effect of PS and CLASI activity on modified
Skindex 2913 subscales
Two-way ANOVAyielded a main effect for PS (yes
vs no), on all 3 subscales of the modified Skindex-
2913 (symptom [P = .007], emotion [P = .003], and
function [P = .000]) such that the PS group had
significantly worse scores on average compared with
the not-PS group (Fig 3). A main effect for CLASI
activity (mild [0-9] vs moderate and severe [ 9]) was
also significant for the symptom (P = .007) and
emotion (P = .003) subscales but not for the function
subscale (P = .10) of the modified Skindex-2913
such that the patients with more severe (higher)
CLASI activity scores had significantly worse scores
on average compared with patients with mild
(lower) CLASI activity scores.Within PS group strata: high/low PS and
mild/moderate-severe CLASI activity
ANOVA showed that the effect of PS group strata
was significant for symptom, emotion, and function
(F = 11.90, P = .000; F = 13.76, P = .000; and F = 14.97,
P = .000). Post hoc analyses using Bonferroni crite-
rion for significance showed that the high PS group
scored significantly worse on the symptom scale
compared with the low PS group within each disease
activity strata (mild activity group: low PS, M = 26.8,
SD = 19.2 vs high PS, M = 47.7, SD = 22.9, P = .001;
andmoderate-severe activity group: lowPS,M=37.7,
SD = 12.5 vs high PS, M = 60.8, SD = 16.7, P = .006).
Fig 4. Mean modified Skindex-2913 subscale scores
across high/low photosensitivity (PS ) groups and
mild/moderate-severe activity strata. Mean scores (mean
1 SEM) for modified Skindex-2913 subscales (emotion,
symptoms, functioning). **High PS group scored worse
than low PS group within each disease activity strata on all
3 subscales of modified Skindex-2913 with P\.01. #Mild
activity, high PS group scored worse than moderate-severe
activity, low PS group with P = .01. ns, Not significant.
Fig 3. Mean modified Skindex-2913 subscale scores
between photosensitivity (PS ) and not-PS group. Mean
scores (mean 1 SEM) for modified Skindex-2913 sub-
scales (emotion, symptoms, functioning). *PS group
scored worse on all 3 subscales of modified Skindex-
2913 with P\ .05.
Table III. Mean Cutaneous Lupus Erythematosus
Disease Area and Severity Index activity scores
among 3 photosensitivity groups
N Mean SD P
Not-PS group 40 4.6 5.6 e
PS-suggestive group 23 10 11.7 .072
PS group 91 9.2 9.5 .023*
PS, Photosensitivity.
*There was significant difference between PS and not-PS groups.
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PS group scoring significantly worse than the low
PS group within each disease activity strata (mild
activity group: low PS, M = 29.7, SD = 23.0 vs high PS,
M = 61.4, SD = 24.5, P = .000; and moderate-severe
activity group: low PS, M = 47.5, SD = 25.0 vs high PS,
M = 70.8, SD = 18.1, P = .031). In terms of functioning,
the high PS group scored significantly worse than the
low PS group within and across activity strata such
that the high PS and mild activity group scored
worse than the moderate-severe activity and low PS
group (high PS, mild activity: M = 41.8, SD = 25.5 vs
low PS, moderate-severe activity: M = 19.0, SD = 14.8,
P = .010) (Fig 4).
DISCUSSION
Self-reported PS encompasses all skin-specific or
systemic adverse reactions that the patient tempo-
rally relates to sun exposure. Self-reported PS is very
common among patients with CLE in the United
States. Approximately 68% of our patients experi-
ence PS at a given time during the course of their
disease. SCLE, LET, and ACLE appear to be the most
PS subtypes with the prevalence of self-reported PS
symptoms being 94%, 81%, and 81%, respectively.
Even among the least PS subtype, DLE, more than
50% of patients report experiencing PS. Among thosewith SLE with nonspecific skin manifestations, more
than 75% reported PS. Our results are similar to those
of a US population of patients with SLE in which 73%
reported experiencing PS via visual analog scale14
and among a European CLE population that met SLE
criteria, in which 63% of patients had observed PS.39
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with reports that patients with SCLE and LET are
more likely to be PS by history and by positive
provocative phototest compared with patients with
DLE.12,22,40
We were able to classify patients into PS, not-PS,
and PS-suggestive groups based on two simple
clinical interview questions: ‘‘Have you been expe-
riencing sensitivity to sunlight?’’ and ‘‘Do you have a
history of photosensitivity?’’ The PS group comprised
patients who reported a history of and current
adverse reactions to sunlight. This group more fre-
quently engaged in sun-protective behaviors and
experienced lesions in sun-exposed areas. Further,
the PS group scored worse on the two PS items and
PS scale of the modified Skindex-2913. Our results
suggest that simple interview questions are a reliable
way of determining self-reported PS among patients
with LE.
Both the PS group and PS-suggestive groups
scored worse than the not-PS group on the modified
Skindex-2913 PS items: worry about sun exposure,
avoid outdoor behavior, and PS scale. Interestingly,
only the behavior-related item, ‘‘I avoid outdoor
activities because of my disease,’’ showed a dose
response, with the PS group scoring worse than the
PS-suggestive group and even more so compared
with the not-PS group. These results suggest that
items relating to behavior modification might be
more sensitive predictors of significant PS in lupus.
We found that patients reporting PS had greater
cutaneous disease activity compared with patients
who denied ever experiencing PS. In support of
this observation, patients with PS reported more
impaired quality of life related to cutaneous symp-
toms. Among SLE populations, PS has been associ-
ated with both more severe systemic and more
benign outcomes.41-44 We are unaware, however,
of any association between increased cutaneous
lupus disease activity and PS in lupus. A relationship
between UVR-induced lupus-specific skin lesions
and cutaneous lupus activity is easily extrapolated,
but it is less clear how nonspecific PS reactions
(ones excluding UVR-induced lupus-specific skin
lesions) or sunlight-induced systemic lupus symp-
toms may relate to lasting cutaneous inflammation.
Studies investigating mechanisms that underlie
these general PS reactions within a CLE population
to determine how they might contribute to cutane-
ous lupus-specific disease activity would be very
interesting.
Patients with CLE who experience PS have a
worse quality of life with respect to their daily
functioning, symptoms, and emotions and the effect
of PS appears to be independent of cutaneous lupusdisease activity. Despite the effect of CLASI activity
on symptoms and emotions, patients with more PS
report greater impairment related to symptoms and
emotions compared with patients who have less PS
but experience a similar degree of cutaneous lupus
disease activity. The effect of PS on daily functioning
is most striking, with highly PS patients reporting
significantly more impaired functioning compared
with patients with more severe cutaneous lupus
activity but less PS.
Prior studies have reported impaired quality of life
among patients with SLE and PS,14 but we report on
the impact of PS on quality of life in a primarily CLE
population. This study contributes to a growing body
of research suggesting that quality of life in cutane-
ous lupus is quite poor, and in fact, is as poor as in
patients with common chronic medical conditions
such as congestive heart failure and type 2 diabe-
tes.32 PS is common among patients with CLE and is
an important contributor to poor quality of life.
Patients’ daily functioning is profoundly impacted
not only by the cutaneous and systemic reactions to
sun exposure but also by compliance with strict sun
avoidance and sun-protective behaviors.
As outlined in a recent editorial,45 photopro-
tection for patients with lupus is of utmost impor-
tance. However, sun avoidance between 10 AM
and 3 PM and daily use of a hat and sun-
protective clothing may not be easily adopted
behaviors. Compliance with strict photoprotection
may impair patients’ daily functioning. It is im-
portant for physicians to be aware of this when
advising patients on photoprotection. Because
photoprotection with sunscreens and clothing is
difficult and sun avoidance can dramatically im-
pact quality of life, future studies investigating the
mechanisms that underlie self-reported PS in lu-
pus are imperative.
One limitation of this study is that patients were
treated at the medical dermatology clinic at the
Hospital of the University of Pennsylvania, which is
a referral-only center. As such, these patients might
have more severe disease than patients with cutane-
ous lupus who are treated by general dermatologists.
Second, the cross-sectional nature of this study does
not allow for examination of a causal relationship
between PS and cutaneous disease activity or poor
quality of life. Because we ask patients to recall
adverse reactions to sunlight, there could be an
element of information bias that could artificially
inflate the prevalence of self-reported PS in the
sample. Lastly, patients with self-perceived PS might
alter their behavior or worry more about sunlight,
which could confound the results regarding the
effect of PS on quality of life.
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Self-reported PS encompasses any adverse reac-
tion that is identified by the patient and is thought
to be related to sun exposure. Self-reported PS is
very common among patients with CLE. Simple
interview-style questions can be used to distinguish
a population of patients who ascribe to sun-related
adverse effects, have photodistributed skin lesions,
and engage in sun-protective behaviors, all of which
confirm that the patient is PS. Patients with PS can be
further distinguished by the modified Skindex-2913
items, of which the behavior-related item may be
most sensitive. PS is associatedwith worse cutaneous
lupus activity and poor quality of life related to
symptoms and emotions. PS profoundly affects
functioning such that patients with the most PS
experience more impaired daily functioning com-
pared with those with less PS but more severe
cutaneous lupus disease activity.
Future studies should attempt to characterize the
various phenotypes of self-reported PS. PS surveys
should incorporate behavioral items because they
might be significant indicators of PS. Finally, the
mechanisms underlying self-reported PS should be
investigated to determine how they contribute to
disease activity and to explore their use in the
development of novel therapies that prevent or
ameliorate sunlight-induced adverse symptoms
among patients with LE.
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